MTOR and B-cell non-Hodgkin lymphoma: We further checked the importance of PTEN status in determining the mTOR inhibitor resistance by comparing the effect of mTOR inhibitors against PTEN-deleted B-cell lymphoma cells (BJAB) and checked the ability of mTOR inhibitors as the modulator of drug resistance in such PTEN-deleted condition.